Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 8/20 | 0.42 |
| ▸ | NOS3 | P29474 | 7/20 | 0.42 |
| ▸ | NOS2 | P35228 | 4/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3475116 | 0.89 | NOS1 (0.42) | NOS1NOS3NOS2SLC6A2SLC6A3 | |
| SCHEMBL3073906 | 0.88 | SLC6A2 (0.51) | SLC6A2SLC6A3SLC6A4SCN9AMAP4K1 | |
| SCHEMBL3476093 | 0.87 | SLC6A2 (0.39) | NOS1NOS3NOS2SLC6A2SLC6A3 | |
| SCHEMBL3086267 | 0.86 | GSK3B (0.41) | SLC6A2SLC6A3SLC6A4SCN9AMAP4K1 | |
| SCHEMBL3081614 | 0.85 | SLC6A2 (0.39) | NOS1NOS3NOS2SLC6A2SLC6A3 | |
| SCHEMBL3477064 | 0.85 | SLC6A2 (0.39) | NOS1NOS3NOS2SLC6A2SLC6A3 | |
| SCHEMBL3073915 | 0.85 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4MAP4K1SSTR4 | |
| SCHEMBL3093435 | 0.82 | SSTR4 (0.37) | SLC6A2SLC6A3SLC6A4MAP4K1SSTR4 | |
| SCHEMBL3076948 | 0.82 | SLC6A2 (0.50) | SLC6A2SLC6A3SLC6A4MAP4K1SSTR4 | |
| SCHEMBL3087454 | 0.82 | ROCK2 (0.43) | MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987252-B2 | Aryloxy- and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20100210624-A1 | ARYLOXY- AND HETEROARYLOXY-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210624-A1 | ARYLOXY- AND HETEROARYLOXY-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ADRA2B, HTR2B, ADRA1B | NOS1 1895/4885NOS3 1519/4885NOS2 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.